{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T21:58:40Z","timestamp":1794693520145,"version":"4.9.1"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000},"content-version":"vor","delay-in-days":67,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.critrevonc.2023.104035","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T21:15:01Z","timestamp":1685049301000},"page":"104035","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The 2022 Assisi Think Tank Meeting: White paper on optimising radiation therapy for breast cancer"],"prefix":"10.1016","volume":"187","author":[{"given":"C.","family":"Aristei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Kaidar-Person","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Boersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Offersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Arenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bourgier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Pfeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Kouloulias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"B\u00f6l\u00fckba\u015f\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Meattini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Coles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Montero","family":"Luis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Masiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.G.","family":"Morganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Perrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Tombolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Krengli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Marazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Trigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Borghesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ciabattoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Rato\u0161a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Valentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Poortmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2023.104035_bib1","unstructured":"Alliance A011202 trial, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01901094. (Accessed 5 May 2023)."},{"key":"10.1016\/j.critrevonc.2023.104035_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102967","article-title":"The 2018 assisi think tank meeting on breast cancer: International expert panel white paper","volume":"151","author":"Arenas","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104035_bib3","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10549-016-3998-2","article-title":"The 2016 Assisi Think Tank Meeting on breast cancer: white paper","volume":"160","author":"Aristei","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2023.104035_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103774","article-title":"Ways to improve breast cancer patients' management and clinical outcome: The 2020 Assisi Think Tank Meeting","volume":"177","author":"Aristei","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104035_bib5","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ijrobp.2017.03.016","article-title":"NRG Oncology-Radiation Therapy Oncology Group Study 1014: 1-year toxicity report from a phase 2 study of repeat breast-preserving surgery and 3-dimensional conformal partial-breast reirradiation for in-breast recurrence","volume":"98","author":"Arthur","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104035_bib6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1001\/jamaoncol.2019.4320","article-title":"Effectiveness of breast-conserving surgery and 3-dimensional conformal partial breast reirradiation for recurrence of breast cancer in the ipsilateral breast: The NRG Oncology\/RTOG 1014 Phase 2 Clinical Trial","volume":"6","author":"Arthur","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2023.104035_bib7","unstructured":"Association between tumor immune response and risk of recurrence in breast cancer patients treated with radiotherapy. Available at: https:\/\/www.straaleterapi.dk\/media\/1930\/demet-oezcan-uk.pdf (Accessed: 10 January2023)."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104035_bib8","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ijrobp.2019.05.070","article-title":"Radiated, reconstructed, recurred","volume":"105","author":"Bagley","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2023.104035_bib9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.radonc.2021.12.036","article-title":"Post-operative re-irradiation with hyperthermia in locoregional breast cancer recurrence: temperature matters","volume":"167","author":"Bakker","year":"2021","journal-title":"Radiother. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104035_bib10","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.clbc.2020.01.012","article-title":"A Phase II Study of pembrolizumab in cancer","volume":"20","author":"Barroso-Sousa","year":"2020","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.critrevonc.2023.104035_bib11","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981-22023 AMAROS trial","author":"Bartels","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104035_bib12","doi-asserted-by":"crossref","first-page":"djw192","DOI":"10.1093\/jnci\/djw192","article-title":"Relevance of tumor-infiltrating immune cell composition and functionality for disease outcome in breast cancer.","volume":"109","author":"Bense","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104035_bib13","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clon.2021.12.007","article-title":"Model-based selection for proton therapy in breast cancer: development of the national indication protocol for proton therapy and first clinical experiences.","volume":"34","author":"Boersma","year":"2022","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104035_bib14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.4048\/jbc.2021.24.e27","article-title":"The Italian Association of Radiotherapy and Oncology Recommendation for breast tumor recurrence: grades of recommendation, assessment, development and evaluation criteria","volume":"24","author":"Bottero","year":"2021","journal-title":"J. Breast Cancer"},{"issue":"27","key":"10.1016\/j.critrevonc.2023.104035_bib15","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1200\/JCO.21.00934","article-title":"Management of the axilla in early-stage breast cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline.","volume":"39","author":"Brackstone","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.critrevonc.2023.104035_bib16","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1200\/JCO.19.02806","article-title":"Multidisciplinary management of locoregional recurrent breast cancer","volume":"38","author":"Buchholz","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104035_bib17","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3389\/fonc.2018.00612","article-title":"Radiation, immune checkpoint blockade and the abscopal effect: A critical review on timing, dose and fractionation.","volume":"8","author":"Buchwald","year":"2018","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2023.104035_bib18","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","article-title":"Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer.","volume":"32","author":"Burstein","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104035_bib19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijrobp.2017.01.244","article-title":"Tolerance of the brachial plexus to high-dose reirradiation","volume":"98","author":"Chen","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2023.104035_bib20","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.radonc.2020.05.051","article-title":"Interaction between lymphopenia, radiotherapy technique, dosimetry, in lung cancer patients receiving combined immunotherapy and radiotherapy","volume":"150","author":"Chen","year":"2020","journal-title":"Radiother. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104035_bib21","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.amjsurg.2008.06.018","article-title":"The survival impact of the choice of surgical procedure after ipsilateral breast cancer recurrence","volume":"196","author":"Chen","year":"2008","journal-title":"Am. J. Surg."},{"key":"10.1016\/j.critrevonc.2023.104035_bib22","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.radonc.2021.10.010","article-title":"Proton reirradiation for recurrent or new primary breast cancer in the setting of prior breast irradiation","volume":"165","author":"Choi","year":"2021","journal-title":"Radiother. Oncol."},{"issue":"10099","key":"10.1016\/j.critrevonc.2023.104035_bib23","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0140-6736(17)31145-5","article-title":"Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non- inferiority trial","volume":"390","author":"Coles","year":"2017","journal-title":"Lancet"},{"issue":"10265","key":"10.1016\/j.critrevonc.2023.104035_bib24","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104035_bib25","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/annonc\/mdz398","article-title":"Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis","volume":"30","author":"Dafni","year":"2019","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104035_bib26","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.ijrobp.2015.12.361","article-title":"Hyperthermia and radiation therapy in locoregional recurrent breast cancers: a systematic review and meta-analysis","volume":"94","author":"Datta","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2 Pt 1","key":"10.1016\/j.critrevonc.2023.104035_bib27","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/1078-0432.728.11.2","article-title":"Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer.","volume":"11","author":"Demaria","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"17","key":"10.1016\/j.critrevonc.2023.104035_bib28","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody.","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104035_bib29","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.","volume":"15","author":"Donker","year":"2014","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104035_bib30","first-page":"249","article-title":"Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma.","volume":"54","author":"Donskov","year":"2007","journal-title":"Dan. Med. Bull."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104035_bib31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","article-title":"Tolerance of normal tissue to therapeutic irradiation","volume":"21","author":"Emami","year":"1991","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104035_bib32","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1078-0432.CCR-16-3001","article-title":"Breast cancer immunotherapy: facts and hopes.","volume":"24","author":"Emens","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104035_bib33","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.","volume":"32","author":"Emens","year":"2021","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104035_bib34","article-title":"Reirradiation for locoregional recurrent breast cancer","volume":"6","author":"Fattahi","year":"2020","journal-title":"Adv. Radiat. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104035_bib35","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S1470-2045(18)30380-2","article-title":"Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial","volume":"19","author":"Galimberti","year":"2018","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104035_bib36","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/jama.2011.90","article-title":"Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.","volume":"305","author":"Giuliano","year":"2011","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.critrevonc.2023.104035_bib37","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2017.11470","article-title":"Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Zoo11 (Alliance) randomized clinical trial.","volume":"318","author":"Giuliano","year":"2017","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104035_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-054365","volume":"11","author":"Goyal","year":"2021","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104035_bib39","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jtho.2019.10.002","article-title":"Three-year overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC - Update from PACIFIC","volume":"15","author":"Gray","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104035_bib40","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.radonc.2013.03.026","article-title":"GEC-ESTRO Breast Cancer Working Group. Accelerated partial breast irradiation with interstitial brachytherapy as second conservative treatment for ipsilateral breast tumour recurrence: multicentric study of the GEC-ESTRO Breast Cancer Working Group","volume":"108","author":"Hannoun-Levi","year":"2013","journal-title":"Radiother. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104035_bib41","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ijrobp.2020.12.029","article-title":"Salvage mastectomy versus second conservative treatment for second ipsilateral breast tumor event: a propensity score-matched cohort analysis of the GEC-ESTRO Breast Cancer Working Group Database","volume":"110","author":"Hannoun-Levi","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2023.104035_bib42","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.radonc.2021.06.032","article-title":"Postmastectomy radiation therapy following pathologic complete nodal response to neoadjuvant chemotherapy: A prelude to NSABP B-51?","volume":"162","author":"Haque","year":"2021","journal-title":"Radiother. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104035_bib43","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00066-015-0939-7","article-title":"Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO). DEGRO practical guidelines for radiotherapy of breast cancer VI: therapy of locoregional breast cancer recurrences","volume":"192","author":"Harms","year":"2016","journal-title":"Strahlenther. Onkol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104035_bib44","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/cncr.32599","article-title":"A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer.","volume":"126","author":"Ho","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104035_bib45","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ijrobp.2020.05.011","article-title":"Optimizing radiation therapy to boost systemic immune responses in breast cancer: a critical review for breast radiation oncologists.","volume":"108","author":"Ho","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104035_bib46","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer.","volume":"9","author":"Ho","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2023.104035_bib47","unstructured":"https:\/\/www.nrgoncology.org\/ciro-breast. (Accessed 5 May 2023)."},{"key":"10.1016\/j.critrevonc.2023.104035_bib48","unstructured":"https:\/\/www.cancer.org\/cancer\/breast-cancer\/understanding-a-breast-cancer-diagnosis\/breast-cancer-survival-rates.html (Accessed: 10 January 2023)."},{"issue":"32","key":"10.1016\/j.critrevonc.2023.104035_bib49","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1200\/JCO.2014.56.5838","article-title":"Radiation field design in the ACOSOG Zoo11 (Alliance) trial","volume":"32","author":"Jagsi","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104035_bib50","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3389\/fphar.2020.00170","article-title":"Poly (ADP-Ribose) Polymerase (PARP) inhibitors and radiation therapy","volume":"11","author":"Jannetti","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.critrevonc.2023.104035_bib51","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41523-018-0061-y","article-title":"Hypothesis: can the abscopal effect explain the impact of adjuvant radiotherapy on breast cancer mortality?","volume":"4","author":"Jatoi","year":"2018","journal-title":"NPJ Breast Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104035_bib52","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.clon.2017.11.004","article-title":"Re-irradiation and hyperthermia in breast cancer","volume":"30","author":"Kaidar-Person","year":"2018","journal-title":"Clin. Oncol. (R. Coll. Radiol. )"},{"key":"10.1016\/j.critrevonc.2023.104035_bib53","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.radonc.2019.04.010","article-title":"ESTRO ACROP consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant-based immediate reconstruction for early stage breast cancer","volume":"137","author":"Kaidar-Person","year":"2019","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104035_bib54","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.radonc.2021.09.012","article-title":"A Delphi study and international consensus recommendations: the use of bolus in the setting of postmastectomy radiation therapy for early breast cancer","volume":"164","author":"Kaidar-Person","year":"2021","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104035_bib55","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.radonc.2021.07.015","article-title":"Tricks and tips for target volume definition and delineation in breast cancer: Lessons learned from ESTRO breast courses","volume":"162","author":"Kaidar-Person","year":"2021","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104035_bib56","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.radonc.2022.05.006","article-title":"The association of internal mammary and medial supraclavicular lymph node radiation technique with clinical outcomes: results from the EORTC 22922\/10925 randomised trial","volume":"172","author":"Kaidar-Person","year":"2022","journal-title":"Radiother. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104035_bib57","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/PPO.0000000000000557","article-title":"With our powers combined: exploring parp inhibitors and immunotherapy","volume":"27","author":"Kasherman","year":"2021","journal-title":"Cancer J."},{"key":"10.1016\/j.critrevonc.2023.104035_bib58","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.canrad.2013.07.148","article-title":"Indications potentielles de la tomoth\u00e9rapie h\u00e9lico\u00efdale dans les cancers du sein [Potential indications for helical tomotherapy in breast cancers]","volume":"18","author":"Lamberth","year":"2014","journal-title":"Cancer Radio."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104035_bib59","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/jmrs.96","article-title":"Review of deep inspiration breath-hold techniques for the treatment of breast cancer","volume":"62","author":"Latty","year":"2015","journal-title":"J. Med. Radiat. Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104035_bib60","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1245\/s10434-019-08075-3","volume":"27","author":"Leonardi","year":"2020","journal-title":"Ann. Surg. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104035_bib61","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.radonc.2013.05.010","article-title":"Re-irradiation and hyperthermia after surgery for recurrent breast cancer","volume":"109","author":"Linthorst","year":"2013","journal-title":"Radiother. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104035_bib62","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2015.04.019","article-title":"Local control rate after the combination of re-irradiation and hyperthermia for irresectable recurrent breast cancer: Results in 248 patients","volume":"117","author":"Linthorst","year":"2015","journal-title":"Radiother. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104035_bib63","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: optimizing outcomes in melanoma","volume":"14","author":"Luke","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"32","key":"10.1016\/j.critrevonc.2023.104035_bib64","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1200\/JCO.2011.40.8369","article-title":"Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27","volume":"30","author":"Mamounas","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"Suppl","key":"10.1016\/j.critrevonc.2023.104035_bib65","first-page":"15","volume":"37","author":"Mamounas","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104035_bib66","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S1470-2045(21)00539-8","article-title":"European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer","volume":"23","author":"Meattini","year":"2022","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104035_bib67","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s11547-022-01563-9","article-title":"The Italian Association for Radiotherapy and Clinical Oncology (AIRO) position statements for postoperative breast cancer radiation therapy volume, dose, and fractionation","volume":"127","author":"Meattini","year":"2022","journal-title":"Radiol. Med."},{"issue":"33","key":"10.1016\/j.critrevonc.2023.104035_bib68","doi-asserted-by":"crossref","first-page":"35051","DOI":"10.18632\/oncotarget.6036","article-title":"Re-irradiation for locally recurrent refractory breast cancer","volume":"6","author":"Merino","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2023.104035_bib69","first-page":"0829","article-title":"Acute toxicity after loco regional breast radiation therapy in the randomized DBCG SKAGEN trial 1","volume":"Suppl 1)","author":"Milo","year":"2022","journal-title":"Radiother. Oncol."},{"issue":"10257","key":"10.1016\/j.critrevonc.2023.104035_bib70","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104035_bib71","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10549-019-05221-z","article-title":"GEC-ESTRO APBI classification as a decision-making tool for the management of 2nd ipsilateral breast tumor event","volume":"176","author":"Montagne","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2023.104035_bib72","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.breast.2020.01.003","article-title":"Second conservative treatment for second ipsilateral breast tumor event: a systematic review of the different re-irradiation techniques","volume":"49","author":"Montagne","year":"2020","journal-title":"Breast"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104035_bib73","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/jamaoncol.2017.3625","article-title":"Management of node-positive axilla in breast cancer in 2017","volume":"4","author":"Morrow","year":"2018","journal-title":"Sel. Right Option JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2023.104035_bib74","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/1471-2407-11-197","article-title":"Re-surgery and chest wall re-irradiation for recurrent breast cancer: a second curative approach","volume":"11","author":"M\u00fcller","year":"2011","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104035_bib75","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","article-title":"Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial","volume":"6","author":"Nanda","year":"2020","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104035_bib76","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","article-title":"Effect of pembrolizumab plus neo-adjuvant chemotherapy on pathological complete response in women with early-stage breast cancer.","volume":"6","author":"Nanda","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2023.104035_bib77","unstructured":"NCCN breast cancer guidelines version 4.23 https:\/\/www.nccn.org\/professionals\/physician _gls\/pdf\/breast.pdf. (Accessed 5 May 2023)."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104035_bib78","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.clbc.2021.03.007","article-title":"Advances in combining radiation and immunotherapy in breast cancer","volume":"21","author":"Nguyen","year":"2021","journal-title":"Clin. Breast Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104035_bib79","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.radonc.2014.11.030","article-title":"ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer","volume":"114","author":"Offersen","year":"2015","journal-title":"Radiother. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104035_bib80","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.radonc.2015.12.027","article-title":"ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, version 1.1","volume":"118","author":"Offersen","year":"2016","journal-title":"Radiother. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104035_bib81","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.radonc.2015.10.017","article-title":"Reirradiation and hyperthermia for irresectable locoregional recurrent breast cancer in previously irradiated area: size matters","volume":"117","author":"Oldenborg","year":"2015","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104035_bib82","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2022.03.008","article-title":"Postmastectomy radiotherapy in high-risk breast cancer patients given adjuvant systemic therapy. A 30-year long-term report from the Danish breast cancer cooperative group DBCG 82bc trial","volume":"170","author":"Overgaard","year":"2022","journal-title":"Radiother. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104035_bib83","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41523-022-00404-2","article-title":"Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +\/- trastuzumab in patients with breast cancer brain metastases","volume":"8","author":"Page","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.critrevonc.2023.104035_bib84","article-title":"Cctg MA.39 tailor RT: a randomized trial of regional radiotherapy in biomarker low-risk node-positive breast cancer (NCT03488693).Journal of Clinical Oncology 37:15_suppl","author":"Parulekar","year":"2019","journal-title":"TPS602-TPS602"},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104035_bib85","first-page":"114","article-title":"Radiotherapy as a tool to elicit clinically actionable signaling pathways in cancer","volume":"19","author":"Petroni","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104035_bib86","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1158\/2326-6066.CIR-19-0338","article-title":"Radiotherapy cooperates with IL15 to induce antitumor immune responses","volume":"8","author":"Pilones","year":"2020","journal-title":"Cancer Immunol. Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104035_bib87","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1415369","article-title":"Internal mammary and medial supraclavicular irradiation in breast cancer","volume":"373","author":"Poortmans","year":"2015","journal-title":"New Engl. J. Med"},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104035_bib88","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S1470-2045(20)30472-1","article-title":"Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922\/10925): 15-year results of a randomised, phase 3 trial","volume":"21","author":"Poortmans","year":"2020","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2023.104035_bib89","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/jnci\/djab113","article-title":"Side effects 15 years after lymph node irradiation in breast cancer: randomized EORTC trial 22922\/10925","volume":"113","author":"Poortmans","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104035_bib90","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.ijrobp.2020.03.020","article-title":"5-year update of a multi-institution, prospective phase 2 hypofractionated postmastectomy radiation therapy trial","volume":"107","author":"Poppe","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104035_bib91","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.ccell.2021.05.009","article-title":"Durvalumab with olaparib and paclitaxel for high-risk HER2- negative stage II\/III breast cancer: results from the adaptively randomized I-SPY trial","volume":"39","author":"Pusztai","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2023.104035_bib92","unstructured":"RADCOMP Breast Atlas v.3 - bigreduced.pdf (nrgoncology.org) (Accessed 5 May 2023)."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104035_bib93","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1016\/j.prro.2016.08.009","article-title":"Postmastectomy radiotherapy: an American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology focused guideline update","volume":"6","author":"Recht","year":"2016","journal-title":"Pract. Radiat. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104035_bib94","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1148\/radiol.2253011913","article-title":"Locally recurrent breast cancer: pulse dose rate brachytherapy for repeat irradiation following lumpectomy - a second chance to preserve the breast","volume":"225","author":"Resch","year":"2002","journal-title":"Radiology"},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104035_bib95","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ctrv.2015.03.011","article-title":"The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant","volume":"41","author":"Reynders","year":"2015","journal-title":"Cancer Treat. Rev."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104035_bib96","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/jnci\/djab108","article-title":"PD-L1 immunohistochemistry assay comparison in atezolizumab plus nab-paclitaxel treated advance triple negative breast cancer","volume":"113","author":"Rugo","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"issue":"22","key":"10.1016\/j.critrevonc.2023.104035_bib97","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"New Engl. J. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104035_bib98","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.annonc.2020.01.072","article-title":"Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study","volume":"31","author":"Schmid","year":"2020","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104035_bib99","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"New Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104035_bib100","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104035_bib101","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.annonc.2020.01.072","article-title":"Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study","volume":"31","author":"Schmid","year":"2020","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104035_bib102","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2023.104035_bib103","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.radonc.2020.07.035","article-title":"Toxicity in combination immune checkpoint inhibitor and radiation therapy: a systematic review and meta-analysis","volume":"151","author":"Sha","year":"2020","journal-title":"Radiother. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2023.104035_bib104","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1002\/cncr.27400","article-title":"Outcome after ipsilateral breast tumor recurrence in patients who receive accelerated partial breast irradiation","volume":"118","author":"Shah","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2023.104035_bib105","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1748-717X-8-13","article-title":"Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy","volume":"8","author":"Skinner","year":"2013","journal-title":"Radiat. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104035_bib106","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/S0360-3016(00)01378-X","article-title":"True recurrence vs new primary ipsilateral breast tumor relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management","volume":"48","author":"Smith","year":"2000","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2023.104035_bib107","first-page":"126","article-title":"Selection criteria for early breast cancer patients in the DBCG proton trial - the randomised phase III trial strategy","volume":"27","author":"Stick","year":"2021","journal-title":"Clin. Transl. Radiat. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104035_bib108","doi-asserted-by":"crossref","first-page":"e818","DOI":"10.1634\/theoncologist.2018-0606","article-title":"Increased mortality with repeat lumpectomy alone after ipsilateral breast tumor recurrence","volume":"24","author":"Su","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2023.104035_bib109","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.729250","article-title":"Stereotactic body radiotherapy immunological planning - a review with a proposed theoretical model","volume":"12","author":"Swamy","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104035_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103223","article-title":"Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: a systemic review and meta-analysis of randomized clinical trials.","volume":"159","author":"Tarantino","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"36","key":"10.1016\/j.critrevonc.2023.104035_bib111","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1200\/JCO.22.00044","article-title":"Internal mammary node irradiation in patients with node-positive breast cancer: fifteen-year results from the Danish Breast Cancer Group Internal Mammary Node Study","volume":"40","author":"Thorsen","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104035_bib112","doi-asserted-by":"crossref","first-page":"5732","DOI":"10.1245\/s10434-022-11866-w","article-title":"Preservation of axillary lymph nodes compared with complete dissection in T1-2 breast cancer patients presenting one or two metastatic sentinel lymph nodes: the SINODA-ONE multicenter randomized clinical trial","volume":"29","author":"Tinterri","year":"2022","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104035_bib113","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1832760","article-title":"Immunotherapy as sensitizer for local radiotherapy","volume":"9","author":"Vanneste","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2023.104035_bib114","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity.","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104035_bib115","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ijrobp.2022.03.007","article-title":"Evaluating regional node irradiation allocation and association with oncologic outcomes in NSABP B-18, B-27, B-40 and B-41","volume":"113","author":"Vega","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2023.104035_bib116","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.critrevonc.2018.01.003","article-title":"A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors.","volume":"123","author":"Venkatesulu","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104035_bib117","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/jso.23629","article-title":"Conservative surgery for ipsilateral breast tumor recurrence","volume":"110","author":"Vila","year":"2014","journal-title":"J. Surg. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104035_bib118","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","article-title":"Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial","volume":"25","author":"Voorwerk","year":"2019","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104035_bib119","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.ejso.2019.02.008","article-title":"Repeat breast-conserving therapy for ipsilateral breast cancer recurrence: A systematic review","volume":"45","author":"Walstra","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104035_bib120","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10549-021-06154-2","article-title":"Repeat breast-conserving treatment of ipsilateral breast cancer recurrence: a nationwide survey amongst breast surgeons and radiation oncologists in the Netherlands","volume":"187","author":"Walstra","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104035_bib121","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1245\/s10434-016-5571-y","article-title":"CALOR trial investigators. Poor prognosis after second locoregional recurrences in the CALOR Trial","volume":"24","author":"Wapnir","year":"2017","journal-title":"Ann. Surg. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104035_bib122","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1415340","article-title":"Regional nodal irradiation in early-stage breast cancer","volume":"373","author":"Whelan","year":"2015","journal-title":"New Engl. J. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104035_bib123","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S1470-2045(22)00482-X","article-title":"De-escalation of radiotherapy after primary chemotherapy in cT1\u20132N1 breast cancer (RAPCHEM; BOOG 2010\u201303): 5-year follow-up results of a Dutch, prospective, registry study.","volume":"23","author":"de Wild","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2023.104035_bib124","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jss.2020.07.045","article-title":"Prognosis of surgical treatment after ipsilateral breast tumor recurrence","volume":"258","author":"Wu","year":"2021","journal-title":"J. Surg. Res"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104035_bib125","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/cncr.25505","article-title":"Local, regional, and systemic recurrence rates in patients undergoing skin-sparing mastectomy compared with conventional mastectomy","volume":"117","author":"Yi","year":"2011","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104035_bib126","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157164","article-title":"Optimizing timing of immunotherapy improves control of tumors by hypofractionated radiation therapy","volume":"11","author":"Young","year":"2016","journal-title":"PLoS One"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823001233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823001233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:49:19Z","timestamp":1760903359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842823001233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":126,"alternative-id":["S1040842823001233"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104035","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The 2022 Assisi Think Tank Meeting: White paper on optimising radiation therapy for breast cancer","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104035"}}